Role of Nucleobindin-2 in the Clinical Pathogenesis and Treatment Resistance of Glioblastoma

Glioblastoma (GBM) stands as the most prevalent primary malignant brain tumor, typically resulting in a median survival period of approximately thirteen to fifteen months after undergoing surgery, chemotherapy, and radiotherapy. Nucleobindin-2 (NUCB2) is a protein involved in appetite regulation and...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	I-Cheng Lin, Chih-Hui Chang, Yoon Bin Chong, Shih-Hsun Kuo, Yu-Wen Cheng, Ann-Shung Lieu, Tzu-Ting Tseng, Chien-Ju Lin, Hung-Pei Tsai, Aij-Lie Kwan
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2023-10-01
Sarja:	Cells
Aiheet:	glioblastoma Nucleobindin-2 chemotherapy radiotherapy
Linkit:	https://www.mdpi.com/2073-4409/12/19/2420
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!